SLC5A2 and chronic kidney disease: The KDIGO 2020 clinical practice guidelines for diabetic kidney disease [36] recommend that most patients with T2DM, CKD, and eGFR ≥ 30 mL/min per 1.73 m2 would benefit from treatment with both metformin and a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce the risk of cardiovascular events and kidney outcomes.